---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-262539"
form_type: "8-K"
ticker: "SEPN"
cik: "0001984086"
company_name: "Septerna, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:11:32.274969+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Septerna reports Q3 2024 net loss of $20.5M; cash runway into H2 2027 after IPO

## Summary
- Net loss of $20.5M for Q3 2024; R&D expenses $17.8M, G&A $4.9M.
- Cash, equivalents, and marketable securities $137.5M as of Sep 30, 2024; plus $302.6M net IPO proceeds in Oct 2024 extend runway into H2 2027.
- Phase 1 trial of SEP-786 (oral PTH1R agonist for hypoparathyroidism) ongoing; data expected mid-2025.
- SEP-631 (MRGPRX2 NAM for CSU) in IND-enabling studies; TSHR NAM program for Graves' disease progressing.
- Jae Kim, M.D. appointed CMO in September 2024.

## SEC filing metadata
- accession: 0001193125-24-262539
- form_type: 8-K
- ticker: SEPN
- cik: 0001984086
- company_name: Septerna, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/0001193125-24-262539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1984086/000119312524262539/d888285d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-262539
- JSON: https://secwatch.observer/filing/0001193125-24-262539.json
- Plain text: https://secwatch.observer/filing/0001193125-24-262539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.